Anebulo Pharmaceuticals (NASDAQ: ANEB) releases FY 2025 results and update

Rhea-AI Filing Summary

Anebulo Pharmaceuticals, Inc. furnished a current report describing the release of its financial results for the quarter and fiscal year ended June 30, 2025 and a related business update. The company issued a press release on September 29, 2025 covering these results, which is included as Exhibit 99.1. The report states that this information is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and will only be incorporated into other securities filings if specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/29/2025 - 04:15 PM Learn about SEC filing dates

FAQ

What did Anebulo Pharmaceuticals (ANEB) report in this 8-K filing?

Anebulo Pharmaceuticals furnished a report stating that it issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2025 and provided a business update.

Which period do the reported Anebulo Pharmaceuticals (ANEB) results cover?

The results cover Anebulo Pharmaceuticals’ quarter and fiscal year ended June 30, 2025.

What exhibits are included with Anebulo Pharmaceuticals’ (ANEB) 8-K?

The 8-K includes Exhibit 99.1, a press release dated September 29, 2025, and Exhibit 104, the cover page of the Inline XBRL document.

Is the Anebulo Pharmaceuticals (ANEB) earnings press release considered filed with the SEC?

No. The report specifies that the information in the 8-K, including Exhibit 99.1, is furnished rather than filed and is not subject to Section 18 liabilities of the Exchange Act unless specifically incorporated by reference elsewhere.

Who signed the Anebulo Pharmaceuticals (ANEB) 8-K report?

The report was signed on behalf of Anebulo Pharmaceuticals, Inc. by Richard Anthony Cunningham, its Chief Executive Officer and Principal Executive Officer.

false 0001815974 0001815974 2025-09-29 2025-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 29, 2025

ANEBULO PHARMACEUTICALS, INC

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40388		85-1170950
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Anebulo Pharmaceuticals, Inc. 1017 Ranch Road 620 South, Suite 107 Lakeway, TX		78734
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (512) 598-0931

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $.0.001 par value per share		ANEB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On September 29, 2025, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2025 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated September 29, 2025
104		Cover Page of Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANEBULO PHARMACEUTICALS, INC.
Date: September 29, 2025	By:	/s/ Richard Anthony Cunningham
		Richard Anthony Cunningham
		Chief Executive Officer (Principal Executive Officer)